Boom - Faron to present new BEXMAB translational and clinical data in HR-MDS at EHA 202613 May 2026 07:03
Faron Pharmaceuticals Ltd | Press Release | May 13, 2026 at 09:00:00 EEST
New translational insights and clinical efficacy will be showcased at EHA 2026, with further context discussed during a post‑EHA webcast on 15 June 2026
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that an abstract for its BEXMAB Phase 1/2 study has been accepted as a poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden, 11–14 June 2026.
The BEXMAB study investigates bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This acceptance marks a continuation of the scientific momentum established in 2025, where bexmarilimab abstracts were showcased across five major global oncology and hematology conferences.
“These data provide important new insight into how bexmarilimab acts within the bone marrow microenvironment when combined with azacitidine. Understanding the immune and blast-level changes associated with treatment is key as we seek to improve outcomes for patients with higher-risk MDS, where therapeutic options remain limited,” said Dr. Mika Kontro, Principal Investigator of the BEXMAB study and Associate Professor at University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology.
The data to be presented at EHA will dive into the details of the mechanism of action of bexmarilimab plus azacitidine in MDS, describing the treatment-induced immune cell changes in the bone marrow and its effect on malignant blasts. These translational insights, complement the robust clinical efficacy, featuring a 45% complete remission (CR) rate in treatment-naïve higher-risk (HR)-MDS and a 14.5-month median overall survival in the relapsed/refractory setting. These outcomes notably surpass historical benchmarks for SoC azacitidine as a monotherapy.
Abstract details:
Title: Translational insights and clinical efficacy with bexmarilimab and azacitidine in HR-MDS in the BEXMAB phase 1/2 study
Session: Poster Session 1
Presentation Time/Date: Friday, 12 June (18:45 - 19:45 CEST)
Post‑EHA webcast
Faron will host a live webcast on Monday, 15 June 2026, following the EHA Congress. The webcast will be hosted by Faron management and will feature Dr. Mika Kontro, Principal Investigator of the BEXMAB study and presenting author of Faron’s EHA poster.
The webcast will focus on the broader clinical and scientific context of the BEXMAB programme and will include a live Q&A session.
Registration is now open at: https://faron.videosync.fi/eha-2026
Sign In
Follow the stocks
